Defining Retinal and Choroidal Structures Using Hyperspectral Imaging (NCT07530783) | Clinical Trial Compass
TerminatedNot Applicable
Defining Retinal and Choroidal Structures Using Hyperspectral Imaging
Stopped: This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.
679 participantsStarted 2016-02-25
Plain-language summary
This study investigates a novel, non-invasive imaging technique called hyperspectral retinal imaging to improve the identification and characterisation of retinal and choroidal structures in both healthy and diseased eyes. Hyperspectral imaging captures retinal images across multiple wavelengths of light, generating detailed spectral information that may reveal biological and structural features not visible with conventional retinal photography.
Approximately 1000 participants will undergo retinal imaging at specialist eye clinics in Melbourne, Australia. The study aims to determine whether hyperspectral imaging can detect spectral signatures associated with retinal and optic nerve diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration, and whether these signatures correlate with disease severity.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 years and older
* Able to provide informed consent
* Willing and able to attend study imaging sessions
* Participants with healthy eyes or diagnosed retinal/optic nerve disease (including but not limited to diabetic retinopathy, glaucoma, and age-related macular degeneration)
* Adequate media clarity to permit retinal imaging as determined by investigator
Exclusion Criteria:
* Inability to provide informed consent
* Known history of narrow anterior chamber angles or risk of acute angle closure where pupil dilation is contraindicated
* Ocular media opacities preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous hemorrhage)
* Any condition that, in the opinion of the investigator, would make participation unsafe or compromise study data quality
* Allergy or contraindication to pharmacologic mydriatic agents used for pupil dilation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Optimisation and characterisation of hyperspectral retinal imaging spectral signatures in normal and diseased eyes
Timeframe: Single study visit (approximately 60 minutes), with additional optional follow-up imaging visits for longitudinal data collection where applicable.